Table 4.
Comparison of Adverse Effects
| Variable | 14-Day BQT (n=81) |
14-Day MIT (n=89) |
p-value |
|---|---|---|---|
| Any side effects | 47 (58.0) | 54 (60.7) | 0.725 |
| Nausea | 8 (9.9) | 8 (9.0) | 0.507 |
| Diarrhea | 6 (7.4) | 9 (10.1) | 0.381 |
| Headache | 9 (11.1) | 8 (9.0) | 0.645 |
| Dyspepsia | 16 (19.8) | 21 (23.5) | 0.377 |
| Dizziness | 7 (8.6) | 6 (6.7) | 0.641 |
| Bitter taste | 9 (11.1) | 10 (11.2) | 0.622 |
| Bloating | 13 (16.0) | 12 (13.5) | 0.509 |
| Fatigue | 27 (33.4) | 28 (31.4) | 0.794 |
| Soreness | 16 (19.7) | 20 (22.4) | 0.899 |
| Skin rash | 2 (2.5) | 4 (4.5) | 0.684 |
| Moderate side effects | 7 (8.6) | 7 (7.8) | 0.898 |
Data are presented as the number (%).
BQT, bismuth-based quadruple therapy; MIT, metronidazole-intensified triple therapy.